Peng Wang Appointed WuXi PharmaTech VP of Discovery Biology
WuXi PharmaTech (Shanghai, China) has appointed Peng Wang, PhD as vice president of discovery biology.
WuXi PharmaTech (Shanghai, China) has appointed Peng Wang, PhD as vice president of discovery biology. Prior to joining WuXi PharmaTech, Wang was a research fellow at the Schering-Plough Research Institute, where he worked for 18 years. He has extensive experience in discovery biology, including target validation research, assay development, screening, in vitro, and in vivo biological and pharmacological studies, and biomarker research. In his new role, Wang will oversee the WuXi PharmaTech’s portfolio of discovery biology service offerings.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
